Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.

NCT07334912 is registered in ClinicalTrials.gov with Aelis Farma as lead sponsor.

NCT NCT07334912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07334912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2b Trial to Assess the Efficacy, Safety and Tolerability of AEF0217 for 24 Weeks in Adults and Older Adolescents With Down Syndrome.
Lead sponsor
Aelis Farma
Phase
Phase 2
Overall status
Recruiting
Start date
December 22, 2025
Completion date
December 31, 2027
Enrollment
188 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome (trisomy 21)